Małopolskie Centrum Biotechnologii UJ

What Małopolskie Centrum Biotechnologii UJ does

Małopolskie Centrum Biotechnologii UJ (MCB UJ) is a multidisciplinary life sciences research institute operating within Jagiellonian University in Kraków, Poland. Established around 2010, the centre runs 19 active research groups, 4 independent grant holders, and a Dioscuri Centre of Excellence, covering structural biology, genomics, proteomics, metabolomics, bioinformatics, molecular biology, virology, photobiology, and developmental biology. It serves academic researchers, early-career scientists, and pharmaceutical/biotechnology industry clients through shared infrastructure access, collaborative research projects, and contract services, with a stated workforce of 11-50 employees and 30% international researcher representation.

MCB UJ's technology stack centres on advanced core facilities - cryo-electron microscopy, X-ray crystallography, advanced mass spectrometry proteomics, high-throughput genomics, flow cytometry, laser scanning confocal microscopy, and biomolecular interaction characterisation - housed in a building recognised by the PZITB Budowa Roku 2013 prize for modern technology facilities. The institute co-develops two flagship infrastructure platforms inscribed on Poland's official Roadmap for Research Infrastructures: TwinMed, an AI- and HPC-driven multi-scale digital patient twin platform (molecular to whole-organism) developed with Cyfronet AGH, Wrocław Supercomputing Centre, and Sano for personalised medicine; and POL-INSTRUCT, an interdisciplinary structure-guided drug discovery platform coordinated with the Institute of Bioorganic Chemistry PAN. Research outputs include the first global Urban RNA Virus Atlas (~55,000 RNA viruses, 77% novel, across 102 cities / 31 countries, published in Nature Communications) and structural discoveries on ruthenium- and osmium-based anticancer compounds published in Nucleic Acids Research.

The institute is primarily funded through competitive research grants from Polish and EU agencies - National Science Centre (NCN), NAWA, the Polish Ministry of Science and Higher Education, and the European Commission (Horizon Europe, Twinning) - supplemented by institutional core funding from Jagiellonian University and fee-for-service revenue from its nine Core Facilities and "Oferta dla biznesu" business collaboration programme. Notable recent grant awards include the IMPACT-Cell Horizon Europe Twinning project (€1,493,592.73 over 36 months, Q4 2026 start), a TOP200 NAWA grant of 2,377,600 PLN, and NCN OPUS and SONATA awards totalling over 6.5 million PLN. Commercial pricing is not published; access is arranged via multi-year grant contracts and per-project fee agreements.

Name

Małopolskie Centrum Biotechnologii UJ

Legal name

Małopolskie Centrum Biotechnologii - Uniwersytet Jagielloński

Website

https://mcb.uj.edu.pl

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Academic life sciences research institute at Jagiellonian University in Kraków, Poland, operating 19 research groups spanning structural biology, genomics, proteomics, virology, and bioinformatics. Funded primarily through competitive grants, offering fee-for-service core facilities and contract research to academic and industry partners.

Ownership category

akta.pro rank

Product category

Biotechnology Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)

akta.pro industry

PRIMARYEDAHAGAI

Biomedical Sciences & Medical Research Institutes (University-Based)

Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

SECONDARYHLAGAJAC

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAEAD

Genomics & Molecular Diagnostics (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGAIAF

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

Keywords

• Structural biology research
• Biotechnology research institute
• Proteomics core facility
• Drug discovery platform
• Digital twin biomedicine

Headquarters

HQ city

Kraków

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Competitive Grant Funding: MCB UJ is primarily funded through competitive research grants from national agencies (National Science Centre NCN, NAWA) and EU programmes (Horizon Europe, Twinning). Major recent grants include IMPACT-Cell Twinning (1,493,592.73 EUR), TOP200 NAWA (2,377,600 PLN), OPUS SONATA grants (2,984,730 PLN, 3.5+ million PLN, 49,500 PLN), supporting specific research programmes and personnel.
2. Core Facility Services: MCB operates shared research infrastructure (Core Facilities) available to external academic and industry researchers, providing fee-for-service access to equipment and expertise in genomics, proteomics, structural biology, flow cytometry, confocal microscopy, and animal studies.
3. Business Collaboration / Contract Research: MCB offers dedicated business collaboration services through its 'Oferta dla biznesu' (Business Collaboration) programme, providing contract research and technical services to industry partners.
4. Institutional Core Funding: Base institutional funding from Jagiellonian University and the Polish Ministry of Science and Higher Education supports the centre's operations and infrastructure maintenance.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

MCB UJ is a multidisciplinary life sciences research institute at Jagiellonian University that operates advanced core facilities (cryo-EM, X-ray crystallography, proteomics, genomics, flow cytometry, confocal microscopy) and delivers collaborative research projects in structural biology, genomics, proteomics, bioinformatics, virology, photobiology, and personalised medicine. It offers fee-for-service core facility access to academic and industry researchers, runs flagship infrastructure platforms (TwinMed digital twin centre, POL-INSTRUCT drug discovery platform), and conducts grant-funded research programmes.

Product overview

Małopolskie Centrum Biotechnologii UJ is a research institute at Jagiellonian University in Krakow, Poland, offering advanced scientific infrastructure and research services rather than commercial products. Its core offerings include state-of-the-art Core Facilities (Cell Bank, Genomics, Structural Biology, Proteomics, Animal Facility, Confocal Microscopy, Flow Cytometry, Biomolecular Interactions), research initiatives like the TwinMed digital twin center and POL-INSTRUCT drug discovery platform, and collaborative projects such as the IMPACT-Cell Twinning project. The institute also produces research outputs including the Urban RNA Virus Atlas. Services are available to external researchers and businesses through the 'Oferta dla biznesu' (Business Collaboration) program.

Differentiator

Problem solved

Functional benefit

Products and services

• Core Facilities Infrastructure State-of-the-art research infrastructure including Cell Bank, Genomics Core Facility, Structural Biology Core Facility, Proteomics Core Facility, Animal Facility, Laser Scanning Confocal Microscope, Flow Cytometry Core, and Biomolecular Interaction & Stability Core Facility, available to academic researchers and external clients on a fee-for-service basis.
• TwinMed - Centre for Digital Twin Technologies in Biomedicine and Personalised Medicine An advanced system using AI, Big Data, and high-performance computing to create digital representations of patients (digital twins) and enable multi-scale modelling of biological and physiological processes from molecular to organism level, applicable in personalised medicine, diagnostics, and drug design.
• POL-INSTRUCT - Interdisciplinary Platform for Structure-Guided Development of Biologically Active Molecules An interdisciplinary platform supporting the entire drug discovery and development process, with particular focus on structural biology methods. Co-coordinated by the Institute of Bioorganic Chemistry PAN with MCB UJ as a key consortium partner.
• IMPACT-Cell (Integrated Mapping of Proteomic And struCtural Transitions in Cells) A Horizon Europe Twinning project enabling knowledge transfer in advanced proteomics, post-translational modifications analysis, single-cell research methods, visual proteomics, cellular cryo-electron tomography, high-resolution structural biology, and computational modelling, in partnership with EMBL, Lund University, University of Southern Denmark, and Fundación para la Formación e Investigación Sanitarias de la Región de Murcia.
• Business Collaboration Services (Oferta dla biznesu) Contract research and technical services offered to industry partners including pharmaceutical, biotechnology, and diagnostics companies. Provides access to specialised structural biology, cryo-EM, proteomics, and genomics platforms for drug development, target validation, and technology licensing.

Quantifiable outcome

• 55,000 RNA viruses identified, 77% previously unknown to science, across 102 cities in 31 countries
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core.

• ACK Cyfronet AGHcoreTechnology or Integration · 17 August 2026Partner in the TwinMed - Centre for Digital Twin Technologies project, providing high-performance computing infrastructure essential for AI-driven modelling of biological processes and digital patient twin generation.
• Wrocławskie Centrum Sieciowo-Superkomputerowe Politechniki WrocławskiejcoreTechnology or Integration · 17 August 2026Partner in the TwinMed project contributing supercomputing and networking infrastructure to support large-scale biomedical data processing and multi-scale biological modelling.
• SanocoreStrategic or Co-development Partner · 17 August 2026Partner in the TwinMed project for digital twin technologies in biomedicine and personalised medicine, contributing to the development of advanced computational approaches for patient-specific healthcare applications.
• Institute of Bioorganic Chemistry, Polish Academy of Sciences (ICHB PAN)coreStrategic or Co-development Partner · 17 August 2026Coordinator of the POL-INSTRUCT project (Interdisciplinary Platform for Structure-Guided Development of Biologically Active Molecules), with MCB UJ as a key consortium partner providing structural biology expertise for the drug discovery and development platform.
• EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development Partner · 29 July 2026International collaborator in the chromatin recognition research led by Prof. Curtis Davey at MCB, involving EPFL researchers Prof. Ursula Röthlisberger, Dr. Andrea Levy, and Prof. Paul Dyson. The collaboration combined high-resolution structural biology with advanced multi-scale molecular simulations to study Ru and Os anticancer compounds.
• European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development Partner · 28 July 2026EMBL is a partner in the IMPACT-Cell Horizon Europe Twinning project, contributing expertise in advanced proteomics, single-cell methods, cryo-electron tomography, high-resolution structural biology, and computational modelling. The partnership facilitates knowledge transfer and best practice exchange to strengthen MCB's scientific excellence.
• Fundación para la Formación e Investigación Sanitarias de la Región de MurciacoreStrategic or Co-development Partner · 28 July 2026Spanish healthcare research foundation partner in the IMPACT-Cell Twinning project, contributing to the knowledge exchange and collaboration network alongside MCB and three other leading European institutions.
• Syddansk Universitet (University of Southern Denmark)coreStrategic or Co-development Partner · 28 July 2026Danish university partner in the IMPACT-Cell Twinning project, providing scientific collaboration and training support to strengthen MCB's research capabilities in proteomics and structural biology.
• Lunds Universitet (Lund University)coreStrategic or Co-development Partner · 28 July 2026Swedish university partner in the IMPACT-Cell Twinning project, contributing expertise in structural biology and life sciences research to support MCB's scientific development goals.
• Max Planck SocietycoreStrategic or Co-development Partner · 1 January 2024The Dioscuri Programme was initiated by the Max Planck Society and is co-managed with the National Science Centre. The programme strengthens scientific excellence in Central and Eastern Europe, with MCB serving as a host institution for Dioscuri Centre leaders. MCB also hosts the Glatt Lab associated with the Max Planck Society.
• MetaSUB Consortium (Global City Sampling Day)coreStrategic or Co-development Partner · 1 January 2020MCB participates in the international MetaSUB Consortium's Global City Sampling Day (gCSD) initiative, coordinated at MCB by Prof. Paweł Łabaj. The consortium collected urban environmental samples from 102 cities in 31 countries, enabling the creation of the first global urban RNA virus atlas published in Nature Communications.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Premier European intergovernmental life sciences research organization. Listed as an IMPACT-Cell partner, EMBL also serves as a much larger incumbent with comparable structural biology, proteomics, and bioinformatics capabilities, acting as the reference institution MCB aspires to match.
• Wellcome Sanger Institute: UK-based genomics and bioinformatics powerhouse. Comparable in large-scale genomic data generation, bioinformatics, and translational biology, but at substantially larger scale with global research leadership.
• Broad Institute of MIT and Harvard: US-based genomics and biomedical research institute. Comparable in integrative genomic, proteomic, and computational biology approaches, and a leading reference point for digital twin and personalized medicine initiatives.
• Institut Pasteur: Long-established French biomedical research institute with major virology, genomics, and structural biology programs. Overlaps with MCB's virology and infectious disease research, but at significantly larger scale and broader international footprint.

Direct peers

• International Institute of Molecular and Cell Biology (IIMCB): Polish biomedical research institute in Warsaw operating under the Polish Academy of Sciences. Closest national peer with overlapping structural biology, molecular biology, and bioinformatics focus, and competes for the same NCN/NAWA grant funding.
• Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG): Dresden-based Max Planck institute sharing the Dioscuri programme partnership with MCB. Comparable in cell biology, biophysics, and computational biology scope, with a similar mixed structural/quantitative research model.
• Nencki Institute of Experimental Biology, Polish Academy of Sciences: Major Polish life sciences research institute with similar remit in molecular biology, neurobiology, and cell biology. Comparable grant funding profile (NCN, EU) and competing for talent in the same Polish ecosystem.
• Helmholtz Centre for Infection Research (HZI): German Helmholtz research center with comparable infectious disease, vaccine, and microbiome research. Shares EU grant funding ecosystem and competes for talent in adjacent research areas to MCB's virology and MetaSUB microbiome work.
• Institute of Molecular Biology (IMB): German research institute specializing in gene regulation, epigenetics, and DNA biology. Comparable in size and mission to MCB, with overlapping research areas in chromatin biology and quantitative molecular biology.
• Institute of Bioorganic Chemistry, Polish Academy of Sciences (ICHB PAN): Polish Academy of Sciences institute coordinating the POL-INSTRUCT consortium with MCB UJ. Directly comparable in structural biology, drug discovery, and bioorganic chemistry, sharing both grant funding and personnel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookpl-pl.facebook.com/MalopolskieCentrumBiotechnologii
• LinkedInlinkedin.com/company/ma%C5%82opolskie-centrum-biotechnologii-uj

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Małopolskie Centrum Biotechnologii UJ